These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 21788049

  • 1. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
    Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM.
    J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
    [Abstract] [Full Text] [Related]

  • 2. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED, Lamb DJ, Khera M, Murthy L, Lipshultz LI.
    Int J Impot Res; 2008 Sep; 20(6):561-5. PubMed ID: 18843272
    [Abstract] [Full Text] [Related]

  • 3. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS).
    Blick G, Khera M, Bhattacharya RK, Nguyen D, Kushner H, Miner MM.
    Pain Med; 2012 May; 13(5):688-98. PubMed ID: 22536837
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM, Simhan J, Carson CC.
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI.
    Int J Impot Res; 2008 May; 20(2):213-7. PubMed ID: 17898800
    [Abstract] [Full Text] [Related]

  • 6. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A, Rhoden EL.
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [Abstract] [Full Text] [Related]

  • 7. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL, Morgentaler A.
    Int J Impot Res; 2006 Dec; 18(2):201-5. PubMed ID: 16177827
    [Abstract] [Full Text] [Related]

  • 8. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G.
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [Abstract] [Full Text] [Related]

  • 9. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF.
    Cancer; 2007 Feb 01; 109(3):536-41. PubMed ID: 17183557
    [Abstract] [Full Text] [Related]

  • 10. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
    Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD.
    J Androl; 2002 Feb 01; 23(6):922-6. PubMed ID: 12399540
    [Abstract] [Full Text] [Related]

  • 11. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP, Gardette J, Rollet J, Legros JJ.
    BJU Int; 2013 May 01; 111(6):880-90. PubMed ID: 23294726
    [Abstract] [Full Text] [Related]

  • 12. Testosterone supplementation does not worsen lower urinary tract symptoms.
    Pearl JA, Berhanu D, François N, Masson P, Zargaroff S, Cashy J, McVary KT.
    J Urol; 2013 Nov 01; 190(5):1828-33. PubMed ID: 23764078
    [Abstract] [Full Text] [Related]

  • 13. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
    Gould DC, Feneley MR, Kirby RS.
    BJU Int; 2006 Jul 01; 98(1):1-4. PubMed ID: 16831134
    [Abstract] [Full Text] [Related]

  • 14. 12-month observation of testosterone replacement effectiveness in a general population of men.
    Miner MM, Bhattacharya RK, Blick G, Kushner H, Khera M.
    Postgrad Med; 2013 Mar 01; 125(2):8-18. PubMed ID: 23816767
    [Abstract] [Full Text] [Related]

  • 15. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
    Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM.
    J Sex Med; 2011 Nov 01; 8(11):3204-13. PubMed ID: 21834870
    [Abstract] [Full Text] [Related]

  • 16. Testosterone replacement therapy after primary treatment for prostate cancer.
    Agarwal PK, Oefelein MG.
    J Urol; 2005 Feb 01; 173(2):533-6. PubMed ID: 15643240
    [Abstract] [Full Text] [Related]

  • 17. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.
    Rhoden EL, Riedner CE, Morgentaler A.
    J Urol; 2008 May 01; 179(5):1741-4. PubMed ID: 18343420
    [Abstract] [Full Text] [Related]

  • 18. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease.
    Tan RS, Pu SJ.
    Aging Male; 2003 Mar 01; 6(1):13-7. PubMed ID: 12809076
    [Abstract] [Full Text] [Related]

  • 19. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
    Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M.
    Int J Impot Res; 2013 Jan 01; 25(1):24-8. PubMed ID: 22971614
    [Abstract] [Full Text] [Related]

  • 20. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
    Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, Miller MG.
    J Sex Med; 2014 Nov 01; 11(11):2818-25. PubMed ID: 25131184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.